Literature DB >> 32718248

Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial.

Thorsten M Leucker1, Michael J Blaha1, Steven R Jones1, Michael A Vavuranakis1, Marlene S Williams1, Hong Lai2, Thomas H Schindler3, Jacqueline Latina1, Steven P Schulman1, Gary Gerstenblith1.   

Abstract

Entities:  

Keywords:  acute coronary syndrome; cholesterol, LDL; evolocumab; secondary prevention

Year:  2020        PMID： 32718248      PMCID： PMC8323059          DOI： 10.1161/CIRCULATIONAHA.120.046320

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  Circulation       Date:  2018-11-10       Impact factor: 29.690

3.  Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).

Authors:  Konstantinos C Koskinas; Stephan Windecker; Giovanni Pedrazzini; Christian Mueller; Stéphane Cook; Christian M Matter; Olivier Muller; Jonas Häner; Baris Gencer; Carmela Crljenica; Poorya Amini; Olga Deckarm; Juan F Iglesias; Lorenz Räber; Dik Heg; François Mach
Journal:  J Am Coll Cardiol       Date:  2019-08-31       Impact factor: 24.094

4.  Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.

Authors:  Stephen D Wiviott; Christopher P Cannon; David A Morrow; Kausik K Ray; Marc A Pfeffer; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2005-10-18       Impact factor: 24.094

5.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245
  5 in total
  3 in total

1.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

Review 2.  New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease.

Authors:  Achim Leo Burger; Edita Pogran; Marie Muthspiel; Christoph Clemens Kaufmann; Bernhard Jäger; Kurt Huber
Journal:  Biomedicines       Date:  2022-04-22

3.  Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients.

Authors:  Ziwei Ou; Zaixin Yu; Benhui Liang; Lin Zhao; Jianghua Li; Xinli Pang; Qiyun Liu; Cong Xu; Shaohong Dong; Xin Sun; Tangzhiming Li
Journal:  Front Cardiovasc Med       Date:  2022-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.